iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000

PUBT · 2d ago
iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000
  • iBio posted fiscal 2026 revenue of USD 100,000, down 75%.
  • Net loss widened to USD 33.04 million; loss per share narrowed to USD 0.32.
  • Research and development expense climbed to USD 19.64 million on higher consultant and outside-services spending, plus a USD 2.5 million milestone.
  • Cash, cash equivalents and debt-security investments totaled USD 88 million at June 30, 2026; management said financings extended runway into fiscal 2028.
  • Phase 1 IBIO-600 advanced through single ascending dose with 31 of 32 participants dosed; IBIO-610 moved into IND-enabling studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280700PRIMZONEFULLFEED9817493) on August 28, 2026, and is solely responsible for the information contained therein.